OPK
What one share of OPKO Health holds
Pharmaceutical Preparations
We are a diversified healthcare company that seeks to establish industry-leading positions in large and rapidly growing medical markets. Our pharmaceutical business features NGENLA® (somatrogon-ghla), also referred to as Somatrogon (hGH-CTP), a once-weekly human growth hormone injection.
OPKO Health’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.75 |
|---|---|
| Profit | −$0.09 |
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$0.17 |
| Cash and investments | $0.40 |
| Debt | $0.01 |
| Book value | $1.59 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $2.01 | −$0.10 | $0.03 | $0.02 | — | $3.67 |
| 2017 | $1.73 | −$0.55 | $0.08 | −$0.25 | — | $3.30 |
| 2018 | $1.76 | −$0.27 | $0.05 | −$0.24 | — | $2.91 |
| 2019 | $1.51 | −$0.53 | $0.02 | −$0.31 | — | $2.41 |
| 2020 | $2.24 | $0.05 | $0.05 | $0.01 | — | $2.49 |
| 2021 | $2.74 | −$0.05 | $0.05 | $0.01 | — | $2.47 |
| 2022 | $1.40 | −$0.46 | $0.03 | −$0.17 | — | $2.02 |
| 2023 | $1.15 | −$0.25 | $0.02 | −$0.06 | — | $1.99 |
| 2024 | $1.03 | −$0.08 | $0.04 | −$0.30 | — | $2.03 |
| 2025 | $0.81 | −$0.30 | $0.02 | −$0.25 | — | $1.67 |